Su questa pagina
PTCT PTC Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Visualizza su SEC EDGAR ↗ chiudi Ott 2, 2026 10-K/10-Q Lug 30, 2026
$63,46
· % dell'intervallo 52 sett.
· sopra il minimo
· al massimo
$61,23minimo 52 sett.
$90,87massimo 52 sett.
Capitalizzazione di Mercato (MRQ)
$5.29B
P/E (TTM)
-117.5
EPS (TTM)
$-0.54
Ricavi (TTM)
$1.01B
i tuoi badge
Intervallo 52 sett.
$61–$91
Rating Analisti
BUY
Prezzo Obiettivo
$102
P/E
-117.5
ROE
20.6%
Margine di Profitto Netto
-3.8%
La tua barra dei badge è vuota — aggiungi una metrica a piacere in questa pagina.
PTCT Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$63.46
Capitalizzazione di Mercato (MRQ)
$5.29B
P/E (TTM)
-117.5
EPS (TTM)
$-0.54
Ricavi (TTM)
$1.01B
ROE (TTM)
20.6%
D/E Debito/Patrimonio (MRQ)
-3.6
Intervallo 52 sett.
$61–$91
PTCT Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
intervallo
barre
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
Informazioni su PTC Therapeutics, Inc. - Common Stock Panoramica della società da Wikipedia
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.
Products
In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren) marketed for nonsense mutation Duchenne muscular dystrophy. Together, the two products generated revenues of 174 million dollars and 260 million dollars in 2017 and 2018 respectively.
PTC has the commercialization rights for WAYLIVRA (volanesorsen) in Latin America.
In 2018, PTC acquired Agilis Biotherapeutics and a gene therapy candidate, GT-AADC, with its compelling clinical data in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. As of 2024, the AAV based treatment for AADC deficiency has been approved by the FDA and commercialized in the United States as Kebilidi. It is the first FDA-approved gene therapy treatment for AADC deficiency. This same product was granted EMA approval for use in the European Union under the name Upstaza.
Pipeline
In 2020, PTC acquired Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth.
In 2020, PTC announced the FDA approval of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older.
In 2024, Novartis has committed $1 billion upfront in a licensing deal with PTC Therapeutics for an experimental treatment for Huntington’s disease, with the potential for an additional $1.9 billion tied to achieving specific development, regulatory, and commercial milestones. PTC Therapeutics’ therapy, known as PTC518, is an oral medication designed to reduce the production of the mutant protein linked to the genetic mutation responsible for the disease. This mutant protein is believed to contribute to neuronal death, driving disease progression. In June, interim data from a Phase 2 trial indicated that PTC518 successfully lowered levels of the mutant protein in both blood and cerebrospinal fluid.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
settoreHealthcare
industriaBiotechnology
dipendenti991
paeseUS
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi$1.73B2016-12-31 → 2025-12-31
EPS$7.782019-12-31 → 2025-12-31
Flusso di cassa libero$702M2016-12-31 → 2025-12-31
Margine netto-3.8%2016-12-31 → 2025-12-31
Valutazione e Rapporti
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | PTCT | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/E (TTM) | -117.5media 5 anni ≈-2.7 | ≈-2.7 | · | · | |
| P/S (TTM) | 5.2media 5 anni ≈3.8 | ≈3.8 | 55.0 | Sottovalutato | |
| P/B (MRQ) | -32.0media 5 anni ≈481.5 | ≈481.5 | · | · | |
| EV / EBITDA (TTM) | 20.2media 5 anni ≈-5.5 | ≈-5.5 | · | · | |
| Prezzo / FCF (TTM) | -133.2media 5 anni ≈-10.8 | ≈-10.8 | · | · | |
| Prezzo / Flusso di cassa (TTM) | -173.4media 5 anni ≈-12.1 | ≈-12.1 | · | · | |
| EV / Ricavi (TTM) | 3.6media 5 anni ≈3.0 | ≈3.0 | · | · | |
| EV / FCF (TTM) | -91.9media 5 anni ≈-8.4 | ≈-8.4 | · | · | |
| Prezzo / Valore contabile tangibile (MRQ) | -9.3 | · | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | PTCT | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Margine Operativo (TTM) | 12.5%media 5 anni ≈-25.9% | ≈-25.9% | -24.1% | Di prim'ordine | |
| Margine EBITDA (TTM) | 17.9%media 5 anni ≈-13.8% | ≈-13.8% | -24.1% | Di prim'ordine | |
| Margine ante imposte (TTM) | -6.6%media 5 anni ≈-43.8% | ≈-43.8% | -28.9% | Di prim'ordine | |
| Margine di Profitto Netto (TTM) | -3.8%media 5 anni ≈-42.4% | ≈-42.4% | -38.1% | Di prim'ordine | |
| ROA (TTM) | -1.3%media 5 anni ≈-12.6% | ≈-12.6% | -27.7% | Di prim'ordine | |
| ROE (TTM) | 20.6%media 5 anni ≈-299.7% | ≈-299.7% | -40.8% | Debole | |
| ROIC | 1044.7%media 5 anni ≈267.1% | ≈267.1% | -37.7% | Di prim'ordine |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | PTCT | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto (MRQ) | -3.6media 5 anni ≈74.5 | ≈74.5 | · | · | |
| Rapporto corrente (MRQ) | 3.4media 5 anni ≈2.1 | ≈2.1 | 8.3 | Bassa liquidità | |
| Quick Ratio (MRQ) | 3.2media 5 anni ≈2.0 | ≈2.0 | 3.2 | In linea | |
| Debito a lungo termine / Patrimonio netto (MRQ) | -3.2media 5 anni ≈65.1 | ≈65.1 | · | · |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
| Metrica | Tendenza 5 anni | PTCT | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Revenue YoY (Ricavi YoY) | 114.5%media 5 anni ≈41.2% | ≈41.2% | · | · | |
| Revenue CAGR 3Y (CAGR Ricavi 3Y) | 35.3%media 5 anni ≈28.3% | ≈28.3% | · | · | |
| Revenue CAGR 5Y (CAGR Ricavi 5Y) | 35.4% | · | · | · |
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
| Metrica | Tendenza 5 anni | PTCT | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Asset Turnover (Rotazione delle attività) | 0.8media 5 anni ≈0.5 | ≈0.5 | 0.4 | Di prim'ordine | |
| Receivables Turnover (Rotazione dei crediti) | 10.2media 5 anni ≈6.8 | ≈6.8 | 9.7 | In linea | |
| Revenue / Employee (Ricavi / Dipendente) | ≈$1.7M | · | · | · |
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
105.2%
Prossimo report
Nov 02, 2026
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Giugno 2026 | Ago 5, 2026 | $0.92 | $0.43 | 116.4% |
| 31 Marzo 2026 | $-0.03 | $-0.48 | 93.7% | |
| 31 Dicembre 2025 | $-1.67 | $0.04 | -4460.3% | |
| 30 Settembre 2025 | $0.20 | $-1.40 | 114.3% | |
| 30 Giugno 2025 | $-0.83 | $-1.08 | 23.3% | |
| 31 Marzo 2025 | $10.04 | $-0.22 | 4743.8% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Cost of Revenue | · | · | · | · | · | · | $12M | $13M | $5M | $0 | $0 | · | |
| R&D Expense | $455M | $534M | $667M | $651M | $541M | $478M | $257M | $172M | $117M | $118M | $122M | $80M | |
| SG&A Expense | $347M | $301M | $333M | $326M | $286M | $245M | $203M | $154M | $121M | $97M | $82M | $45M | |
| Operating Expenses | $864M | $1.11B | $1.38B | $1.15B | $913M | $813M | $548M | $380M | $259M | $215M | $204M | $125M | |
| Operating Income | $867M | $-303M | $-440M | $-447M | $-374M | $-432M | $-241M | $-116M | $-64M | $-132M | $-167M | $-99M | |
| Other Non-op | $-18M | $7M | $10M | $-49M | $-58M | $85M | $14M | $129.0K | $-1M | $-1M | $-465.0K | $-213.0K | |
| Pretax Income | $697M | $-363M | $-696M | $-587M | $-518M | $-403M | $-240M | $-128M | $-78M | $-142M | $-170M | $-98M | |
| Income Tax | $14M | $176.0K | $-70M | $-28M | $6M | $35M | $12M | $-29.0K | $1M | $569.0K | $485.0K | $-5M | |
| Net Income | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| EPS (Basic) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | · | · | $-2.97 | |
| EPS (Diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | · | · | · | · | $-2.97 | |
| Shares (Basic) | 79,534,290 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| Shares (Diluted) | 88,311,494 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| EBITDA | $906M | $-227M | $-203M | · | $-310M | $-388M | $-209M | $-90M | $-47M | $-132M | $-167M | $-99M |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $985M | $780M | $594M | $280M | $190M | $209M | $288M | $169M | $112M | $58M | $58M | $50M | |
| Short-term Investments | $961M | $360M | $283M | $131M | $584M | $895M | $399M | $58M | $79M | $173M | $281M | $265M | |
| Receivables | $182M | $159M | $161M | $156M | $110M | $70M | $56M | $68M | $40M | $25M | $11M | $4M | |
| Inventory | $80M | $23M | $31M | $22M | $16M | $19M | $19M | $16M | $11M | $0 | · | · | |
| Prepaid Expense | $67M | $44M | $150M | $106M | $55M | $39M | $18M | $9M | $7M | $5M | $6M | $4M | |
| Current Assets | $2.27B | $1.37B | $1.22B | $694M | $954M | $1.23B | $779M | $321M | $249M | $261M | $356M | $324M | |
| PP&E (Net) | $55M | $61M | $87M | $73M | $53M | $34M | $22M | $13M | $8M | $7M | $9M | $9M | |
| PP&E (Gross) | $102M | $94M | $138M | $110M | $80M | $52M | $33M | $20M | $41M | $38M | $37M | $34M | |
| Accum. Depreciation | $47M | $33M | $51M | $37M | $27M | $18M | $12M | $7M | $33M | $31M | $28M | $25M | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $0 | · | · | · | |
| Intangibles | $389M | $119M | $379M | $706M | $725M | $715M | $710M | $701M | $133M | $0 | · | · | |
| Total Assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Accounts Payable | $45M | $17M | $6M | $27M | $23M | $19M | $10M | $6M | $15M | $6M | $6M | $4M | |
| Current Liabilities | $968M | $581M | $603M | $406M | $509M | $277M | $236M | $167M | $82M | $50M | $45M | $32M | |
| Capital Leases | $94M | $75M | $98M | $101M | $74M | $79M | $9M | · | · | · | · | · | |
| Deferred Tax | · | · | $56M | $103M | $137M | $137M | $131M | $122M | $0 | · | · | · | |
| Other Non-current Liabilities | $14M | $21M | $141.0K | $3M | · | $1M | $141.0K | $58.0K | $243.0K | $335.0K | $2M | $2M | |
| Total Liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768M | $235M | $150M | $139M | $35M | |
| Long-term Debt | · | · | · | · | $431M | · | $314M | $153M | $145M | · | · | · | |
| Total Debt | $287M | $285M | $284M | · | $431M | $309M | $314M | $153M | $145M | $98M | $95M | · | |
| Common Stock | $80.0K | $77.0K | $75.0K | $72.0K | $71.0K | $70.0K | $62.0K | $51.0K | $42.0K | $34.0K | $34.0K | $33.0K | |
| Paid-in Capital | $2.75B | $2.57B | $2.47B | $2.31B | $2.12B | $2.17B | $1.80B | $1.29B | $967M | $856M | $820M | $722M | |
| Retained Earnings | $-2.96B | $-3.65B | $-3.28B | $-2.66B | $-2.10B | $-1.63B | $-1.19B | $-939M | $-814M | $-735M | $-593M | $-423M | |
| AOCI | $11M | $-26M | $-1M | $5M | $-24M | $-61M | $-11M | $1M | $4M | $-1M | $-1M | $-737.0K | |
| Stockholders' Equity | $-205M | $-1.10B | $-819M | $-347M | $1M | $482M | $594M | $351M | $156M | $120M | $226M | $298M | |
| Liabilities + Equity | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Shares Outstanding | 81,474,366 | 77,704,188 | 75,708,889 | 73,104,692 | 70,828,226 | 69,718,096 | 61,935,870 | 50,606,147 | 41,612,395 | 34,169,410 | 33,916,559 | 32,898,392 |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $39M | $76M | $237M | $129M | $64M | $43M | $32M | $26M | $18M | $3M | $3M | · | |
| Stock-based Comp | $75M | $75M | $102M | $110M | $104M | $70M | $42M | $33M | $31M | $35M | $34M | $19M | |
| Deferred Tax | $-3.0K | $-56M | $-47M | $-34M | $377.0K | $6M | $9M | $0 | $199.0K | $-199.0K | $0 | $0 | |
| Amort. of Intangibles | $25M | $61M | $223M | $117M | $55M | $37M | $28M | $23M | $15M | $0 | $0 | · | |
| Restructuring | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Other Non-cash | $-85M | $161M | $177M | · | $105M | $124M | $70M | $41M | $20M | · | · | · | |
| Operating Cash Flow | $711M | $-108M | $-158M | $-357M | $-251M | $-194M | $-99M | $-28M | $-10M | $-104M | $-124M | $-57M | |
| CapEx | $9M | $7M | $28M | $32M | $28M | $18M | $14M | $7M | $3M | $2M | $3M | $5M | |
| Investing Cash Flow | $-862M | $44M | $-177M | $290M | $219M | $-562M | $-387M | $-43M | $13M | $104M | $-21M | $-145M | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | $-49.0K | |
| Stock Issued | · | · | · | · | · | $28M | $324M | $118M | $0 | $0 | $0 | $236M | |
| Net Stock Activity | · | · | · | · | · | $28M | $324M | $118M | · | $0 | · | $236M | |
| Financing Cash Flow | $331M | $256M | $646M | $168M | $21M | $669M | $613M | $132M | $44M | $968.0K | $154M | $237M | |
| Net Change in Cash | $203M | $185M | $314M | $99M | $-19M | $-79M | $126M | $58M | $53M | $299.0K | $8M | $34M | |
| Taxes Paid | $37M | $18M | $14M | $5M | $8M | $26M | $2M | $2M | $1M | $943.0K | $111.0K | $0 | |
| Free Cash Flow | $702M | $-114M | $-187M | · | $-280M | $-212M | $-112M | $-35M | $-13M | $-105M | $-127M | $-62M |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 50.1% | -37.5% | -46.9% | · | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% | -454.6% | -393.8% | |
| Net Margin | 39.4% | -45.0% | -66.8% | · | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% | -463.6% | -371.4% | |
| Pretax Margin | 40.2% | -45.0% | -74.2% | · | -96.2% | -105.8% | -78.2% | -48.4% | -40.0% | -171.1% | -462.3% | -390.0% | |
| EBITDA Margin | 52.3% | -28.1% | -21.6% | · | -57.6% | -102.0% | -68.1% | -33.8% | -24.0% | -159.7% | -454.6% | -393.8% | |
| ROA | 29.7% | -20.2% | -34.8% | · | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.8% | -48.6% | -38.6% | |
| ROE | -331.5% | 33.8% | 84.1% | · | -985.1% | -88.3% | -40.0% | -34.8% | -57.2% | -82.2% | -65.0% | -43.1% | |
| ROIC | 1044.7% | 37.2% | 74.0% | · | -87.4% | -59.4% | -27.8% | -23.0% | -21.7% | -60.9% | -52.3% | -31.7% |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 2.4 | 2.0 | · | 1.9 | 4.4 | 3.3 | 1.9 | 3.0 | 5.3 | 7.8 | 10.0 | |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 | 4.2 | 3.1 | 1.8 | 2.8 | 5.2 | 7.7 | 9.8 | |
| Debt / Equity | -1.4 | -0.3 | -0.3 | · | 300.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · | |
| LT Debt / Equity | · | -0.3 | -0.3 | · | 196.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · |
Efficienza
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.4 | 0.5 | · | 0.3 | 0.2 | 0.2 | 0.4 | 0.6 | 0.3 | 0.1 | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | 0.7 | · | 0.9 | · | · | · | |
| Receivables Turnover | 10.2 | 5.1 | 5.9 | · | 6.0 | 6.1 | 5.0 | 4.9 | 6.0 | 4.6 | 4.7 | 9.3 |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-2.52 | $-14.13 | $-10.81 | · | $0.02 | $6.91 | $9.60 | $6.93 | $3.76 | $3.50 | $6.66 | $9.07 | |
| Revenue / Share | $19.60 | $10.50 | $12.53 | · | $7.64 | · | · | · | · | · | · | $0.80 | |
| Cash Flow / Share | $8.05 | $-1.40 | $-2.12 | · | $-3.57 | · | · | · | · | · | · | $-1.81 | |
| Cash / Share | $12.09 | $10.03 | $7.85 | · | $2.68 | $3.00 | $4.65 | $3.35 | $2.69 | $1.71 | $1.71 | $1.51 | |
| EPS (TTM) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-3.21 | $-3.21 | $-3.21 | $-3.21 | $-2.97 |
Tassi di Crescita
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 114.5% | -14.0% | 34.2% | 29.8% | 41.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 35.3% | 14.4% | 35.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 35.4% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Net Income TTM | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| Market Cap | $6.19B | $3.51B | $2.09B | · | $2.82B | $4.25B | $2.97B | $1.74B | $694M | $373M | $1.10B | $1.70B | |
| Enterprise Value | $4.53B | $2.65B | $1.49B | · | $2.48B | $3.46B | $2.60B | $1.66B | $648M | $239M | $855M | · | |
| P/E | 9.8 | -9.5 | -3.3 | -4.9 | -5.4 | -9.2 | -11.2 | -10.7 | -5.2 | -3.4 | -10.1 | -17.4 | |
| P/S | 3.6 | 4.3 | 2.2 | · | 5.2 | 11.2 | 9.7 | 6.6 | 3.6 | 4.5 | 29.9 | 67.5 | |
| P/B | -30.1 | -3.2 | -2.5 | · | 1961.8 | 8.8 | 5.0 | 5.0 | 4.4 | 3.1 | 4.9 | 5.7 | |
| P / Cash Flow | 8.7 | -32.6 | -13.2 | · | -11.2 | -21.9 | -30.2 | -62.8 | -69.0 | -3.6 | -8.8 | -29.7 | |
| P / FCF | 8.8 | -30.7 | -11.2 | · | -10.1 | -20.1 | -26.5 | -50.0 | -52.7 | -3.5 | -8.6 | -27.5 | |
| EV / EBITDA | 5.0 | -11.7 | -7.4 | · | -8.0 | -8.9 | -12.5 | -18.6 | -13.9 | -1.8 | -5.1 | · | |
| EV / FCF | 6.5 | -23.2 | -8.0 | · | -8.9 | -16.3 | -23.2 | -47.9 | -49.2 | -2.3 | -6.7 | · | |
| EV / Revenue | 2.6 | 3.3 | 1.6 | · | 4.6 | 9.1 | 8.5 | 6.3 | 3.3 | 2.9 | 23.2 | · | |
| Earnings Yield | 10.2% | -10.5% | -30.4% | -20.4% | -18.6% | -10.9% | -8.9% | -9.3% | -19.2% | -29.4% | -9.9% | -5.7% |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $361M | $273M | $165M | $211M | $179M | $1.18B | $213M | $197M | $187M | $210M | $307M | $197M | $214M | $220M | $167M | $217M | |
| R&D Expense | $99M | $101M | $133M | $100M | $113M | $109M | $125M | $161M | $132M | $116M | $121M | $164M | $186M | $195M | $189M | $165M | |
| SG&A Expense | $81M | $86M | $97M | $84M | $85M | $81M | $85M | $73M | $70M | $73M | $76M | $81M | $88M | $87M | $93M | $80M | |
| Operating Expenses | $212M | $228M | $236M | $208M | $214M | $206M | $376M | $251M | $227M | $256M | $301M | $315M | $423M | $338M | $368M | $285M | |
| Operating Income | $149M | $45M | $-71M | $3M | $-35M | $970M | $-162M | $-55M | $-40M | $-45M | $6M | $-118M | $-210M | $-118M | $-200M | $-68M | |
| Other Non-op | $-3M | $2M | $-13M | $7M | $-6M | $-6M | $9M | $-2M | $-2M | $2M | $19M | $-20M | $1M | $10M | $35M | $-38M | |
| Pretax Income | $98M | $-2M | $-139M | $-23M | $-71M | $930M | $-95M | $-98M | $-86M | $-85M | $-157M | $-167M | $-237M | $-135M | $-190M | $-127M | |
| Income Tax | $14M | $347.0K | $-4M | $-39M | $-6M | $63M | $-29M | $9M | $13M | $7M | $-1M | $-34M | $-39M | $4M | $-19M | $-18M | |
| Net Income | $83M | $-3M | $-135M | $16M | $-65M | $867M | $-66M | $-107M | $-99M | $-92M | $-156M | $-133M | $-199M | $-139M | $-171M | $-109M | |
| EPS (Basic) | $1.01 | $-0.03 | $-1.88 | $0.20 | $-0.83 | $11.09 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| EPS (Diluted) | $0.92 | $-0.03 | $-1.63 | $0.20 | $-0.83 | $10.04 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| Shares (Basic) | 83,006,808 | 82,521,023 | · | 78,471,119 | 78,151,240 | 78,115,836 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| Shares (Diluted) | 92,020,009 | 82,521,023 | · | 87,115,369 | 78,151,240 | 86,385,922 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| EBITDA | $149M | $60M | · | $3M | $-35M | $977M | · | $-55M | $-40M | $10M | · | $-118M | $-210M | $-75M | · | $-68M |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.05B | $834M | $985M | $673M | $1.02B | $1.48B | $780M | $526M | $655M | $548M | · | $165M | $208M | $167M | · | $104M | |
| Short-term Investments | $1.18B | $1.06B | $961M | $1.02B | $972M | $547M | $360M | $487M | $439M | $336M | · | $130M | $130M | $119M | · | $184M | |
| Receivables | $239M | $220M | $182M | $203M | $196M | $210M | $159M | $200M | $187M | $198M | · | $166M | $178M | $202M | · | $124M | |
| Inventory | $91M | $76M | $80M | $53M | $34M | $22M | $23M | $36M | $32M | $30M | · | $36M | $32M | $27M | · | $15M | |
| Prepaid Expense | $58M | $66M | $67M | $64M | $54M | $57M | $44M | $33M | $46M | $56M | · | $44M | $42M | $99M | · | $90M | |
| Current Assets | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | $2.32B | $1.37B | $1.28B | $1.36B | $1.17B | · | $540M | $590M | $613M | · | $517M | |
| PP&E (Net) | $51M | $53M | $55M | $57M | $57M | $59M | $61M | $63M | $66M | $93M | · | $85M | $82M | $79M | · | $67M | |
| PP&E (Gross) | · | · | $102M | · | · | · | $94M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $33M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | · | $82M | $82M | $82M | · | $82M | |
| Intangibles | $403M | $381M | $389M | $396M | $144M | $118M | $119M | $330M | $330M | $330M | · | $423M | $452M | $686M | · | $750M | |
| Total Assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Accounts Payable | $40M | $25M | $45M | $37M | $27M | $15M | $17M | $13M | $24M | $27M | · | $19M | $26M | $26M | · | $21M | |
| Current Liabilities | $771M | $924M | $968M | $866M | $628M | $595M | $581M | $611M | $610M | $575M | · | $492M | $476M | $442M | · | $420M | |
| Capital Leases | $88M | $90M | $94M | $95M | $71M | $74M | $75M | $83M | $79M | $105M | · | $100M | $100M | $100M | · | $102M | |
| Deferred Tax | · | · | · | · | · | · | · | $56M | $56M | $56M | · | $52M | $52M | $103M | · | $137M | |
| Other Non-current Liabilities | $15M | $14M | $14M | $3M | $8M | $22M | $21M | $77.0K | $141.0K | $141.0K | · | $141.0K | $141.0K | $141.0K | · | $5M | |
| Total Liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B | $2.80B | $2.90B | $2.90B | $2.68B | · | $1.93B | $1.92B | $2.07B | · | $1.80B | |
| Long-term Debt | $591M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $591M | $287M | · | $286M | $286M | $286M | · | $285M | $285M | $285M | · | $573M | $573M | $572M | · | $283M | |
| Common Stock | $82.0K | $81.0K | $80.0K | $79.0K | $78.0K | $78.0K | $77.0K | $76.0K | $76.0K | $76.0K | · | $75.0K | $75.0K | $73.0K | · | $71.0K | |
| Paid-in Capital | $2.71B | $2.78B | $2.75B | $2.67B | $2.63B | $2.61B | $2.57B | $2.53B | $2.51B | $2.49B | · | $2.45B | $2.42B | $2.34B | · | $2.22B | |
| Retained Earnings | $-2.88B | $-2.97B | $-2.96B | $-2.83B | $-2.85B | $-2.78B | $-3.65B | $-3.58B | $-3.47B | $-3.38B | · | $-3.13B | $-2.99B | $-2.80B | · | $-2.49B | |
| AOCI | $6M | $8M | $11M | $6M | $7M | $-14M | $-26M | $-4M | $-16M | $-6M | · | $10M | $-1M | $-2M | · | $36M | |
| Stockholders' Equity | $-165M | $-180M | $-205M | $-156M | $-207M | $-186M | $-1.10B | $-1.05B | $-980M | $-894M | $-819M | $-671M | $-579M | $-458M | $-347M | $-227M | |
| Liabilities + Equity | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Shares Outstanding | 83,327,286 | 82,882,024 | 81,474,366 | 79,931,766 | 79,378,145 | 79,225,276 | 77,704,188 | 76,952,124 | 76,900,123 | 76,653,960 | · | 75,459,022 | 75,318,233 | 74,012,034 | · | 71,854,892 |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $16M | $15M | $13M | $11M | $8M | $7M | $7M | $6M | $7M | $55M | $81M | $62M | $51M | $43M | $39M | $34M | |
| Stock-based Comp | $23M | $23M | $19M | $19M | $19M | $18M | $17M | $20M | $19M | $18M | $17M | $27M | $29M | $29M | $27M | $29M | |
| Deferred Tax | · | $-10.0K | $1.0K | · | · | $2.0K | $-56M | $-3.0K | $2.0K | $-1.0K | $4M | $-2.0K | $-51M | $-4.0K | · | · | |
| Amort. of Intangibles | $12M | $12M | $9M | $8M | $4M | $4M | $3M | $3M | $3M | $52M | $77M | $59M | $47M | $39M | $36M | $31M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $23M | $8M | · | · | · | |
| Other Non-cash | · | $-95M | · | · | · | $-22M | · | · | · | $89M | · | · | · | $38M | · | · | |
| Operating Cash Flow | $129M | $-59M | $-34M | $-66M | $-58M | $870M | $-30M | $-77M | $-71M | $71M | $-100M | $-15M | $-14M | $-29M | $-166M | $-38M | |
| CapEx | $2M | $1M | $2M | $3M | $1M | $2M | $4M | $522.0K | $-7M | $10M | $6M | $6M | $6M | $10M | $9M | $5M | |
| Investing Cash Flow | $-123M | $-94M | $34M | $-290M | $-422M | $-184M | $268M | $-43M | $-66M | $-115M | $-94M | $-30M | $-24M | $-29M | $32M | $136M | |
| Financing Cash Flow | $212M | $6M | $303M | $15M | $4M | $9M | $26M | $-18M | $246M | $540.0K | $620M | $3M | $18M | $4M | $303M | $-140M | |
| Net Change in Cash | $216M | $-148M | $312M | $-347M | $-463M | $701M | $256M | $-129M | $104M | $-46M | $429M | $-43M | $-9M | $-62M | $175M | $-54M | |
| Taxes Paid | · | · | $-3M | $936.0K | $36M | $3M | $5M | $7M | $4M | $2M | $524.0K | $4M | $7M | $2M | $893.0K | $1M | |
| Free Cash Flow | · | $-60M | · | · | · | $868M | · | · | · | $61M | · | · | · | $-40M | · | · |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.3% | 16.5% | · | 1.4% | -19.5% | 82.5% | · | -27.7% | -21.5% | -21.6% | · | -60.1% | -98.0% | -53.4% | · | -31.4% | |
| Net Margin | 23.2% | -1.0% | · | 7.5% | -36.2% | 73.7% | · | -54.2% | -53.1% | -43.6% | · | -67.6% | -93.0% | -63.0% | · | -50.3% | |
| Pretax Margin | 27.1% | -0.90% | · | -10.9% | -39.7% | 79.1% | · | -49.8% | -45.9% | -40.3% | · | -84.8% | -111.1% | -61.3% | · | -58.6% | |
| EBITDA Margin | 41.3% | 22.1% | · | 1.4% | -19.5% | 83.1% | · | -27.7% | -21.5% | 4.7% | · | -60.1% | -98.0% | -33.9% | · | -31.4% | |
| ROA | 2.8% | -0.10% | · | 0.71% | -2.9% | 39.0% | · | -6.9% | -6.1% | -5.4% | · | -9.4% | -12.7% | -8.2% | · | -6.1% | |
| ROE | -44.9% | 1.5% | · | -2.6% | 10.9% | -160.5% | · | 12.4% | 12.7% | 13.6% | · | 29.6% | 52.2% | 50.7% | · | 179.2% | |
| ROIC | 30.0% | 48.2% | · | -1.6% | -40.2% | 904.6% | · | 7.7% | 6.7% | 8.1% | · | 96.6% | 2648.9% | -105.7% | · | -104.9% |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 2.4 | · | 2.3 | 3.6 | 3.9 | · | 2.1 | 2.2 | 2.0 | · | 1.1 | 1.2 | 1.4 | · | 1.2 | |
| Quick Ratio | 3.2 | 2.3 | · | 2.2 | 3.5 | 3.8 | · | 2.0 | 2.1 | 1.9 | · | 0.9 | 1.1 | 1.1 | · | 1.0 | |
| Debt / Equity | -3.6 | -1.6 | · | -1.8 | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 | |
| LT Debt / Equity | -3.2 | · | · | · | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 |
Efficienza
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.5 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.7 | 1.3 | · | 1.0 | 0.9 | 5.8 | · | 1.1 | 1.0 | 1.1 | · | 1.4 | 1.4 | 1.3 | · | 2.0 |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.98 | $-2.18 | · | $-1.95 | $-2.60 | $-2.34 | · | $-13.70 | $-12.75 | $-11.66 | · | $-8.89 | $-7.69 | $-6.18 | · | $-3.16 | |
| Revenue / Share | $3.92 | $3.30 | · | $2.42 | $2.29 | $13.61 | · | $2.56 | $2.43 | $2.75 | · | $2.61 | $2.86 | $2.99 | · | $3.03 | |
| Cash Flow / Share | · | $-0.72 | · | · | · | $10.07 | · | · | · | $0.93 | · | · | · | $-0.40 | · | · | |
| Cash / Share | $12.60 | $10.06 | · | $8.41 | $12.82 | $18.68 | · | $6.84 | $8.51 | $7.15 | · | $2.19 | $2.77 | $2.26 | · | $1.45 | |
| EPS (TTM) | $-0.54 | $-2.29 | · | $8.56 | $6.97 | $6.51 | · | $-5.95 | $-6.32 | $-7.69 | · | $-8.65 | $-8.42 | $-7.89 | · | $-7.47 |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.01B | $827M | · | $1.78B | $1.76B | $1.77B | · | $901M | $900M | $928M | · | $798M | $819M | $770M | · | $697M | |
| Net Income TTM | $-38M | $-187M | · | $752M | $629M | $595M | · | $-453M | $-480M | $-579M | · | $-642M | $-618M | $-571M | · | $-531M | |
| Market Cap | $6.80B | $5.65B | · | $4.91B | $3.88B | $4.04B | · | $2.85B | $2.35B | $2.23B | · | $1.69B | $3.06B | $3.59B | · | $3.61B | |
| Enterprise Value | $5.16B | $4.04B | · | $3.50B | $2.17B | $2.30B | · | $2.13B | $1.54B | $1.63B | · | $1.97B | $3.30B | $3.87B | · | $3.60B | |
| P/E | -151.1 | -29.8 | · | 7.2 | 7.0 | 7.8 | · | -6.2 | -4.8 | -3.8 | · | -2.6 | -4.8 | -6.1 | · | -6.7 | |
| P/S | 6.7 | 6.8 | · | 2.8 | 2.2 | 2.3 | · | 3.2 | 2.6 | 2.4 | · | 2.1 | 3.7 | 4.7 | · | 5.2 | |
| P/B | -41.1 | -31.3 | · | -31.5 | -18.8 | -21.7 | · | -2.7 | -2.4 | -2.5 | · | -2.5 | -5.3 | -7.8 | · | -15.9 | |
| P / Cash Flow | · | -95.6 | · | · | · | 4.6 | · | · | · | 31.5 | · | · | · | -121.6 | · | · | |
| EV / Revenue | 5.1 | 4.9 | · | 2.0 | 1.2 | 1.3 | · | 2.4 | 1.7 | 1.8 | · | 2.5 | 4.0 | 5.0 | · | 5.2 | |
| Earnings Yield | -0.66% | -3.4% | · | 14.0% | 14.3% | 12.8% | · | -16.0% | -20.7% | -26.4% | · | -38.6% | -20.7% | -16.3% | · | -14.9% |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ricavi | $1.73B | $807M | $938M | $699M | $539M |
| Margine Operativo % | 50.1% | -37.5% | -46.9% | · | -69.5% |
| Utile netto | $683M | $-363M | $-627M | $-559M | $-524M |
| EPS Diluito | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | -1.4 | -0.3 | -0.3 | · | 300.0 |
| Rapporto corrente | 2.3 | 2.4 | 2.0 | · | 1.9 |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flusso di cassa libero | $702M | $-114M | $-187M | · | $-280M |
Proprietari istituzionali (13F) 403 filer · $8.6B totale · Aggiornato al 30 Settembre 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Detentori
403
Valore detenuto
$8.6B
Nuove posizioni
76
Posizioni chiuse
43
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 76 (+7 vs trimestre precedente) | 43 (-7 vs trimestre precedente) | 140 (+3 vs trimestre precedente) | 114 (+10 vs trimestre precedente) | -1.4M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $1.139.088.671 | 13.964.554 | 13,21% | Azioni |
| VANGUARD GROUP INC | $668.691.300 | 8.803.203 | 7,75% | Azioni |
| RTW INVESTMENTS, LP | $631.875.072 | 7.746.415 | 7,33% | Azioni |
| JANUS HENDERSON GROUP PLC | $489.997.100 | 7.193.433 | 5,68% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $401.986.014 | 4.928.111 | 4,66% | Azioni |
| STATE STREET CORP | $375.136.515 | 4.598.952 | 4,35% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $336.743.228 | 4.128.273 | 3,90% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $305.000.589 | 3.739.127 | 3,54% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $180.089.116 | 2.207.376 | 2,09% | Azioni |
| TORONTO DOMINION BANK | $176.668.031 | 2.165.846 | 2,05% | Azioni |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $159.563.645 | 1.956.156 | 1,85% | Azioni |
| Hood River Capital Management LLC | $141.818.662 | 1.738.613 | 1,64% | Azioni |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $140.519.660 | 1.722.688 | 1,63% | Azioni |
| D. E. Shaw & Co., Inc. | $126.345.323 | 1.548.919 | 1,47% | Azioni |
| TANG CAPITAL MANAGEMENT LLC | $122.355.000 | 1.500.000 | 1,42% | Azioni |
| BANK OF AMERICA CORP /DE/ | $118.462.234 | 1.452.277 | 1,37% | Azioni |
| Driehaus Capital Management LLC | $117.469.528 | 1.440.107 | 1,36% | Azioni |
| FMR LLC | $114.056.206 | 1.398.261 | 1,32% | Azioni |
| Jefferies Financial Group Inc. | $110.693.916 | 1.357.042 | 1,28% | Azioni |
| FULLER & THALER ASSET MANAGEMENT, INC. | $94.361.749 | 1.156.819 | 1,09% | Azioni |
| Pictet Asset Management Holding SA | $93.629.635 | 1.147.844 | 1,09% | Azioni |
| MORGAN STANLEY | $90.026.886 | 1.103.675 | 1,04% | Azioni |
| ARMISTICE CAPITAL, LLC | $87.393.690 | 1.071.395 | 1,01% | Azioni |
| Blue Sparrow, LLC /DE | $85.705.599 | 1.050.700 | 0,99% | Azioni |
| FRANKLIN RESOURCES INC | $83.799.082 | 1.027.327 | 0,97% | Azioni |
| Invesco Ltd. | $76.804.761 | 941.581 | 0,89% | Azioni |
| Palo Alto Investors LP | $74.950.268 | 918.846 | 0,87% | Azioni |
| NORTHERN TRUST CORP | $71.783.966 | 880.029 | 0,83% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64.449.436 | 790.112 | 0,75% | Azioni |
| CITADEL ADVISORS LLC | $60.999.840 | 747.822 | 0,71% | Azioni |
| RENAISSANCE TECHNOLOGIES LLC | $59.015.895 | 723.500 | 0,68% | Azioni |
| Boston Partners | $58.606.553 | 718.574 | 0,68% | Azioni |
| JUPITER ASSET MANAGEMENT LTD | $57.706.697 | 707.450 | 0,67% | Azioni |
| MARSHALL WACE, LLP | $57.489.476 | 704.787 | 0,67% | Azioni |
| JPMORGAN CHASE & CO | $56.073.502 | 684.042 | 0,65% | Azioni |
| ARMISTICE CAPITAL, LLC | $53.836.200 | 660.000 | 0,62% | Opzione Call |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $53.377.940 | 654.382 | 0,62% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $52.017.434 | 637.704 | 0,60% | Azioni |
| GOLDMAN SACHS GROUP INC | $50.430.408 | 618.247 | 0,58% | Azioni |
| LOOMIS SAYLES & CO L P | $48.156.807 | 590.374 | 0,56% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $47.953.943 | 587.887 | 0,56% | Azioni |
| Nuveen, LLC | $47.622.931 | 583.829 | 0,55% | Azioni |
| Bank of New York Mellon Corp | $45.145.865 | 553.462 | 0,52% | Azioni |
| PRINCIPAL FINANCIAL GROUP INC | $44.181.166 | 541.635 | 0,51% | Azioni |
| VOYA INVESTMENT MANAGEMENT LLC | $43.992.251 | 539.319 | 0,51% | Azioni |
| Ensign Peak Advisors, Inc | $41.442.128 | 508.056 | 0,48% | Azioni |
| AMERICAN CENTURY COMPANIES INC | $40.866.277 | 500.995 | 0,47% | Azioni |
| FEDERATED HERMES, INC. | $39.432.896 | 483.424 | 0,46% | Azioni |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $36.050.432 | 441.957 | 0,42% | Azioni |
| Parkman Healthcare Partners LLC | $35.539.315 | 435.691 | 0,41% | Azioni |
Attivisti e proprietari del 5%+ 3 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Brookside Capital Partners Fund, L.P., Brookside Capital Trading Fund, L.P. ×5 depositi | 30 Gennaio 2015 | · | Deposito iniziale | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. (“HBM”) ×2 depositi | 12 Novembre 2014 | · | Deposito iniziale | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. | 05 Luglio 2013 | · | Deposito iniziale | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insider aziendali 37 insider · 15 dirigenti · 20 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER | 04 Agosto 2026 S | 383.868 | 0 | 13 | $-4.219.888 |
| Stuart Walter Peltz | CHIEF EXECUTIVE OFFICER | 31 Gennaio 2023 S | 54.903 | 0 | 0 | $0 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 14 Luglio 2026 S | 83.986 | 0 | 3 | $-652.864 |
| Emily Luisa Hill | CHIEF FINANCIAL OFFICER | 27 Marzo 2023 S | 38.925 | 0 | 0 | $0 |
| Shane William Charles Kovacs | Chief Financial Officer | 09 Maggio 2017 M | 37.850 | 0 | 0 | $0 |
| Claudia De Oliveira Ribeiro Hirawat | President | 15 Gennaio 2015 M | 39.247 | 0 | 0 | $0 |
| Marcio Souza | Chief Operating Officer | 10 Febbraio 2020 M | 6.744 | 0 | 0 | $0 |
| Mark Elliott Boulding | EXEC. VP AND CLO | 17 Agosto 2026 M | 105.272 | 0 | 63 | $-5.955.553 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 09 Luglio 2026 M | 60.299 | 0 | 62 | $-25.989.291 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 17 Giugno 2026 M | 70.199 | 0 | 5 | $-1.941.426 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 10 Giugno 2026 S | 73.411 | 0 | 28 | $-7.477.160 |
| Lee Scott Golden | EVP & CHIEF MEDICAL OFFICER | 02 Aprile 2026 S | 79.115 | 0 | 6 | $-1.081.515 |
| Mark Rothera | Chief Commercial Officer | 24 Maggio 2017 M | 33.739 | 0 | 0 | $0 |
| Tuyen Ong | Chief Medical Officer | 03 Gennaio 2017 A | 6.000 | 0 | 0 | $0 |
| Robert J. Spiegel | Chief Medical Officer | 04 Gennaio 2016 A | 3.239 | 0 | 0 | $0 |
| Glenn Steele JR MD PHD | Direttore | 30 Settembre 2026 M | 22.500 | 0 | 2 | $-1.698.120 |
| Michael Schmertzler | Direttore | 17 Settembre 2026 S | 1.296.594 | 0 | 16 | $-6.313.453 |
| Hege Elisabeth Sollie-Zetlmayer | Direttore | 28 Luglio 2026 A | 52.526 | 0 | 0 | $0 |
| Mary L. Smith | Direttore | 09 Luglio 2026 M | 21.813 | 0 | 2 | $-1.425.060 |
| Jessica Caroline Chutter | Direttore | 24 Marzo 2026 A | 7.333 | 0 | 0 | $0 |
| Stephanie Okey | Direttore | 10 Marzo 2026 M | 8.000 | 0 | 3 | $-1.463.076 |
| Emma Reeve | Direttore | 05 Gennaio 2026 M | 10.666 | 0 | 15 | $-4.229.530 |
| Alethia Young | Direttore | 02 Gennaio 2026 A | 21.067 | 0 | 0 | $0 |
| Allan Steven Jacobson | Direttore | 02 Gennaio 2026 A | 21.451 | 0 | 11 | $-2.912.018 |
| Jerome B Zeldis | Direttore | 02 Gennaio 2026 A | 22.500 | 0 | 0 | $0 |
| William F. Bell Jr. | Direttore | 15 Febbraio 2024 A | 10.333 | 0 | 0 | $0 |
| Dawn Svoronos | Direttore | 09 Giugno 2022 S | 29.017 | 0 | 0 | $0 |
| Cameron Geoffrey Mcdonough | Direttore | 03 Gennaio 2017 A | · | 0 | 0 | $0 |
| Adam Koppel | Direttore | 03 Gennaio 2017 A | 2.333.333 | 0 | 0 | $0 |
| Ronald C Renaud JR | Direttore | 03 Gennaio 2017 A | · | 0 | 0 | $0 |
| Richard Aldrich | Direttore | 08 Giugno 2015 M | 0 | 0 | 0 | $0 |
| Michael L Kranda | Direttore | 16 Marzo 2015 S | 2.242 | 0 | 0 | $0 |
| Axel Bolte | Direttore | 25 Giugno 2013 P | 20.000 | 0 | 0 | $0 |
| HBM Healthcare Investments (Cayman) Ltd. | Proprietario del 10% | 17 Dicembre 2013 S | 2.441.504 | 0 | 0 | $0 |
| David P Southwell | · | 02 Gennaio 2026 A | 20.850 | 0 | 0 | $0 |
| Complete Pharma Holdings II, LLC | · | 28 Aprile 2017 J | 0 | 0 | 0 | $0 |
| CREDIT SUISSE/ | · | 25 Giugno 2013 C | 2.256.882 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 68 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,74% | 4.145 SH | 11 Settembre 2026 | Giornaliero |
| PSCH · Invesco Exchange-Traded Fund Trust … | 2,93% | 79.357 SH | 02 Ottobre 2026 | Giornaliero |
| PBE · Invesco Exchange-Traded Fund Trust | 2,47% | 159.717 SH | 02 Ottobre 2026 | Giornaliero |
| MEDI · Harbor ETF Trust | 1,31% | 7.913 NS | 31 Luglio 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,25% | 18.062 NS | 31 Luglio 2026 | N-PORT |
| RZG · Invesco Exchange-Traded Fund Trust | 1,23% | 22.852 SH | 02 Ottobre 2026 | Giornaliero |
| JSML · Janus Detroit Street Trust | 1,03% | 54.825 NS | 31 Luglio 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0,94% | 145.033 NS | 31 Luglio 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,74% | 98.733 SH | 19 Agosto 2026 | Giornaliero |
| VAMO · Cambria ETF Trust | 0,72% | 11.494 NS | 31 Luglio 2026 | N-PORT |
| VMAX · Lattice Strategies Trust | 0,71% | 5.120 NS | 31 Luglio 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,63% | 46.006 NS | 31 Luglio 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,49% | 658 NS | 31 Luglio 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,42% | 3.031 NS | 31 Luglio 2026 | N-PORT |
| IBB · iShares Trust | 0,40% | 613.266 SH | 11 Settembre 2026 | Giornaliero |
| BRNY · EA Series Trust | 0,39% | 33.006 NS | 31 Luglio 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,37% | 290.018 SH | 19 Agosto 2026 | Giornaliero |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,36% | 5.891 SH | 02 Ottobre 2026 | Giornaliero |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,34% | 75.795 SH | 19 Agosto 2026 | Giornaliero |
| ESSC · Strategy Shares | 0,34% | 1.785 NS | 31 Luglio 2026 | N-PORT |
| IWO · iShares Trust | 0,31% | 664.357 SH | 11 Settembre 2026 | Giornaliero |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,27% | 22.505 NS | 31 Luglio 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,25% | 25.676 NS | 31 Luglio 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,24% | 3.125 NS | 31 Luglio 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,20% | 477.030 SH | 19 Agosto 2026 | Giornaliero |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,19% | 19.797 NS | 31 Luglio 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,19% | 3.667 NS | 31 Luglio 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,19% | 1.099.640 SH | 19 Agosto 2026 | Giornaliero |
| IWM · iShares Trust | 0,18% | 2.118.779 SH | 11 Settembre 2026 | Giornaliero |
| RSSL · Global X Funds | 0,18% | 39.691 NS | 31 Luglio 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,18% | 629 NS | 31 Luglio 2026 | N-PORT |
| ISCG · iShares Trust | 0,16% | 23.005 SH | 11 Settembre 2026 | Giornaliero |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,16% | 65.468 SH | 02 Ottobre 2026 | Giornaliero |
| LRGF · iShares Trust | 0,16% | 84.774 SH | 11 Settembre 2026 | Giornaliero |
| VFMO · VANGUARD WELLINGTON FUND | 0,14% | 35.428 SH | 19 Agosto 2026 | Giornaliero |
| FSMD · FIDELITY COVINGTON TRUST | 0,14% | 51.459 NS | 31 Luglio 2026 | N-PORT |
| FHEQ · Fidelity Greenwood Street Trust | 0,14% | 18.636 NS | 31 Luglio 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,13% | 5.320 SH | 02 Ottobre 2026 | Giornaliero |
| FBUF · Fidelity Greenwood Street Trust | 0,12% | 413 NS | 31 Luglio 2026 | N-PORT |
| FYEE · Fidelity Greenwood Street Trust | 0,11% | 3.600 NS | 31 Luglio 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,10% | 224.327 NS | 31 Luglio 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,08% | 952.071 SH | 19 Agosto 2026 | Giornaliero |
| VB · VANGUARD INDEX FUNDS | 0,08% | 1.902.509 SH | 19 Agosto 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | 0,08% | 211.842 SH | 19 Agosto 2026 | Giornaliero |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,08% | 6.756 NS | 31 Luglio 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,07% | 33.487 NS | 31 Luglio 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,06% | 12.627 NS | 31 Luglio 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,06% | 18.932 SH | 02 Ottobre 2026 | Giornaliero |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,06% | 10.557 SH | 19 Agosto 2026 | Giornaliero |
| ESML · iShares Trust | 0,06% | 22.893 SH | 11 Settembre 2026 | Giornaliero |
| WSML · iShares Trust | 0,04% | 4.360 SH | 11 Settembre 2026 | Giornaliero |
| TILT · FlexShares Trust | 0,01% | 4.108 NS | 31 Luglio 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 2.636.335 SH | 19 Agosto 2026 | Giornaliero |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 66.405 SH | 19 Agosto 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 6.819 SH | 19 Agosto 2026 | Giornaliero |
| ESGV · VANGUARD WORLD FUND | 0,01% | 18.275 SH | 19 Agosto 2026 | Giornaliero |
| ITOT · iShares Trust | 0,01% | 109.219 SH | 11 Settembre 2026 | Giornaliero |
| IWV · iShares Trust | 0,01% | 22.686 SH | 10 Settembre 2026 | Giornaliero |
| DFAC · Dimensional ETF Trust | 0,01% | 43.296 NS | 31 Luglio 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 1.090 NS | 31 Luglio 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 284 NS | 31 Luglio 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 249 NS | 31 Luglio 2026 | N-PORT |
| IJR · iShares Trust | · | 5.061.986 SH | 10 Settembre 2026 | Giornaliero |
| IJT · iShares Trust | · | 784.746 SH | 09 Settembre 2026 | Giornaliero |
| IWN · iShares Trust | · | 114.658 SH | 11 Settembre 2026 | Giornaliero |
| XJR · iShares Trust | · | 11.464 SH | 31 Agosto 2026 | Giornaliero |
| ISCB · iShares Trust | · | 3.281 SH | 11 Settembre 2026 | Giornaliero |
| SMLF · iShares Trust | · | 64.380 SH | 11 Settembre 2026 | Giornaliero |
PTCT Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
rating · 21 analisti
COMPRA
Target mediano
$101.00
+59,2%
6 28,6%
Acquisto forte
11 52,4%
Compra
3 14,3%
Mantieni
1 4,8%
Vendi
0 0,0%
Vendita forte
Target Price a 12 Mesi
14 analisti · 2026-10-01Target medio $101.79 +60,4%
← Sotto tutti i target
Prezzo attuale $63.46
Basso$70.00
Media$101.79
Alto$137.00
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | · |
| SRRK | $4.78B | -13.4 | · | · | -157.9% | · |
| ORKA | $1.48B | -3.3 | · | · | -25.9% | · |
| COGT | $5.72B | -16.4 | · | · | -83.1% | · |
| MIRM | $4.10B | -168.1 | 54.7% | -4.5% | -8.2% | · |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | · |
| ERAS | $1.06B | -8.5 | · | · | -35.7% | · |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | · |
| RLAY | $1.47B | -5.3 | 53.4% | -1800.6% | -44.9% | · |
Segnali di trading Segnali recenti di acquisto/vendita con prezzo di entrata e rapporto rischio/rendimento
Nessun segnale aperto al momento — nessuna scheda è compilata, e questo è onesto.
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Fonte: SEC 10-Q depositato Lug 30, 2026